–6 Based on the benefit from experimental studies, exogenously delivered EPO has been proposed in clinical trials for neuroprotection in retinal neural and vascular diseases,7–10 including diabetic retinopathy and retinopathy of prematurity (ROP).11 This evidence concerns the gene EPO and diabetic retinopathy.